Federal Workforce Shrink Could Cripple FDA Drug & Device Inspections

The Trump administration’s efforts to shrink the federal workforce could significantly hinder FDA’s ability to inspect drug and medical device manufacturing facilities, both domestically and abroad. Legal and industry experts warn that the lack of an adequate workforce could force the agency to rely on remote assessments that contradict the Trump administration’s policies, reduce its international cooperation and delay drug approvals. FDA's core mission includes ensuring that pharmaceutical and medical device manufacturers comply with Current Good Manufacturing Practices (GMPs) under...